论文部分内容阅读
目的分析巨噬细胞抑制因子-1(MIC-1)在胰腺癌患者血清中浓度及其临床价值。方法采用双抗体夹心ELISA法检测150例胰腺癌和胰腺良性疾病患者及120例正常对照人群血清MIC-1浓度,采用电化学发光免疫分析仪和全自动生化分析仪检测上述血清CA199和胆红素浓度。结果胰腺癌组MIC-1浓度显著高于胰腺良性疾病组和对照组(P<0.001);根据ROC曲线,当cut-off值设为946 pg/ml时MIC-1检测胰腺癌的敏感性和特异性分别为80.5%和90.1%,诊断价值优于CA199的74.6%和82.2%;联合检测MIC-1和CA199可使敏感性和特异性升高至85.6%和92.1%;经治疗且疗效评价为有效的患者,其血清MIC-1水平显著下降(P=0.001);胰腺癌患者中胆红素升高组MIC-1浓度显著高于正常组(P=0.011);未转移患者MIC-1浓度高于转移患者(P=0.018)。结论 MIC-1是一项较好的胰腺癌血清标志物,在胰腺癌的诊断和临床转归预测中具有一定的应用价值。
Objective To analyze the serum concentration of macrophage inhibitory factor -1 (MIC-1) in patients with pancreatic cancer and its clinical value. Methods Serum MIC-1 levels in 150 patients with benign pancreatic cancer and pancreatic benign disease and 120 normal controls were detected by double antibody sandwich ELISA. The serum levels of CA199 and bilirubin were detected by using electrochemical luminescence immunoassay analyzer and automatic biochemical analyzer. concentration. Results The MIC-1 concentration in pancreatic cancer group was significantly higher than that in benign pancreatic disease group and control group (P <0.001). According to the ROC curve, the sensitivity of MIC-1 in detecting pancreatic cancer and the cut-off value of 946 pg / The specificity was 80.5% and 90.1% respectively, and the diagnostic value was better than 74.6% and 82.2% of CA199. The combined detection of MIC-1 and CA199 increased the sensitivity and specificity to 85.6% and 92.1% respectively. After treatment and evaluation of curative effect (P = 0.001). In patients with pancreatic cancer, the concentration of MIC-1 in the group with elevated bilirubin was significantly higher than that in the normal group (P = 0.011). The MIC-1 The concentration was higher in metastatic patients (P = 0.018). Conclusion MIC-1 is a good serum marker of pancreatic cancer, which has certain value in the diagnosis and prognosis of pancreatic cancer.